Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/THBS1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/THBS1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/THBS1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/THBS1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/THBS1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000716216 | Oral cavity | EOLP | negative regulation of cell adhesion | 61/2218 | 303/18723 | 2.11e-05 | 3.28e-04 | 61 |
GO:00026968 | Oral cavity | EOLP | positive regulation of leukocyte activation | 77/2218 | 409/18723 | 2.34e-05 | 3.52e-04 | 77 |
GO:190204314 | Oral cavity | EOLP | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | 8/2218 | 13/18723 | 2.84e-05 | 4.12e-04 | 8 |
GO:000250422 | Oral cavity | EOLP | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 14/2218 | 36/18723 | 3.07e-05 | 4.38e-04 | 14 |
GO:001003826 | Oral cavity | EOLP | response to metal ion | 71/2218 | 373/18723 | 3.32e-05 | 4.65e-04 | 71 |
GO:001095124 | Oral cavity | EOLP | negative regulation of endopeptidase activity | 52/2218 | 252/18723 | 4.21e-05 | 5.74e-04 | 52 |
GO:200123724 | Oral cavity | EOLP | negative regulation of extrinsic apoptotic signaling pathway | 26/2218 | 97/18723 | 4.30e-05 | 5.82e-04 | 26 |
GO:190303419 | Oral cavity | EOLP | regulation of response to wounding | 38/2218 | 167/18723 | 5.06e-05 | 6.58e-04 | 38 |
GO:000717916 | Oral cavity | EOLP | transforming growth factor beta receptor signaling pathway | 43/2218 | 198/18723 | 5.48e-05 | 7.03e-04 | 43 |
GO:003059514 | Oral cavity | EOLP | leukocyte chemotaxis | 48/2218 | 230/18723 | 6.07e-05 | 7.64e-04 | 48 |
GO:006104117 | Oral cavity | EOLP | regulation of wound healing | 32/2218 | 134/18723 | 7.29e-05 | 8.89e-04 | 32 |
GO:006032614 | Oral cavity | EOLP | cell chemotaxis | 60/2218 | 310/18723 | 8.04e-05 | 9.66e-04 | 60 |
GO:004340521 | Oral cavity | EOLP | regulation of MAP kinase activity | 39/2218 | 177/18723 | 8.57e-05 | 1.02e-03 | 39 |
GO:005134625 | Oral cavity | EOLP | negative regulation of hydrolase activity | 70/2218 | 379/18723 | 9.98e-05 | 1.14e-03 | 70 |
GO:003432917 | Oral cavity | EOLP | cell junction assembly | 76/2218 | 420/18723 | 1.02e-04 | 1.17e-03 | 76 |
GO:001046624 | Oral cavity | EOLP | negative regulation of peptidase activity | 52/2218 | 262/18723 | 1.21e-04 | 1.34e-03 | 52 |
GO:00105957 | Oral cavity | EOLP | positive regulation of endothelial cell migration | 31/2218 | 133/18723 | 1.51e-04 | 1.62e-03 | 31 |
GO:200037725 | Oral cavity | EOLP | regulation of reactive oxygen species metabolic process | 35/2218 | 157/18723 | 1.51e-04 | 1.62e-03 | 35 |
GO:00105947 | Oral cavity | EOLP | regulation of endothelial cell migration | 47/2218 | 232/18723 | 1.52e-04 | 1.62e-03 | 47 |
GO:00303366 | Oral cavity | EOLP | negative regulation of cell migration | 64/2218 | 344/18723 | 1.57e-04 | 1.67e-03 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
THBS1 | SNV | Missense_Mutation | | c.3229C>T | p.Arg1077Trp | p.R1077W | P07996 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | | c.2476N>G | p.Met826Val | p.M826V | P07996 | protein_coding | tolerated(0.44) | benign(0.015) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | | c.1472N>A | p.Ile491Asn | p.I491N | P07996 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | rs576321057 | c.2318G>A | p.Arg773His | p.R773H | P07996 | protein_coding | deleterious(0.05) | possibly_damaging(0.591) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD |
THBS1 | SNV | Missense_Mutation | novel | c.905N>T | p.Thr302Ile | p.T302I | P07996 | protein_coding | tolerated(0.05) | benign(0.216) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
THBS1 | insertion | Frame_Shift_Ins | novel | c.1869_1870insA | p.Phe624IlefsTer25 | p.F624Ifs*25 | P07996 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.1871_1872insTGTGACCATCAACTCTGTA | p.Thr625ValfsTer30 | p.T625Vfs*30 | P07996 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.236_237insCTTAA | p.Asp80LeufsTer17 | p.D80Lfs*17 | P07996 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
THBS1 | insertion | Nonsense_Mutation | novel | c.237_238insAGTTGAGAGATTTAGCAGCTCAAAAATGTGACCT | p.Asp80SerfsTer2 | p.D80Sfs*2 | P07996 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.988_989insTTCCAGCCCTGCCATCCGCACTAACTACATTGGCCACAAGACA | p.Glu330ValfsTer19 | p.E330Vfs*19 | P07996 | protein_coding | | | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | 5-AZA-2&APOS;-DEOXYCYTIDINE | | 14559817 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | METHYLCELLULOSE | METHYLCELLULOSE | 9016860 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | PROTEIN KINASE C INHIBITOR | | 9223624 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | SIMVASTATIN | SIMVASTATIN | 10543307 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | UVB | | 14962109 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | 5-AZA-2-DEOXYCYTIDINE | | 14559817 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ABT-510 | ABT-510 | |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | VESNARINONE | VESNARINONE | 15356428 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ALL-TRANS RETINOIC ACID | | 9447832 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | RETINOIC ACID | | 1430209 |